A new signal surfaced in an FDA database linking hair loss to biologic drugs, intensifying safety scrutiny around effects that may not appear frequently in controlled trials. The report notes that biologics have expanded rapidly for immune-mediated conditions such as psoriasis and inflammatory bowel disease, increasing the need for post-market pharmacovigilance. The hair-loss association is described as part of a broader pattern: as biologic use grows worldwide, rare or delayed adverse events become more visible. For clinicians and developers, it reinforces the expectation that label language may need updating as real-world safety data accumulates. For biotech companies, the finding also highlights how safety monitoring and risk communication can become a development activity in its own right—especially when biologics are used in chronic settings where long-term effects matter as much as acute safety.